KLK3 and prostate cancer: According to the literature, approximately 240,000 individuals are diagnosed with prostate cancer in the United States annually; however, fewer than 15% eventually die, which has been largely attributed to the widespread application of PSA testing and the effective treatment of early-stage prostate cancer [1,7,8,9,10].